A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Cortice Biosciences
  • Most Recent Events

    • 19 Dec 2013 Last checked against ClinicalTrials.gov
    • 14 Feb 2008 The expected completion date for this trial is now 1 Feb 2007.
    • 11 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top